Inadequate group size compromises conclusions of hemodialysis graft surveillance study  by Krivitski, Nikolai et al.
1520 Letters to the Editor
Renoprotective action of statin
estimated from mapping renal
failure in Japan
To the Editor: We have demonstrated [1, 2] the re-
markable regional difference in the incidence of end-
stage renal disease (ESRD) within Japan, which has an
ethnically homogenous population, suggesting the pres-
ence of factors other than genetics, which may contribute
to the difference. Renoprotective actions of statins, re-
cently proposed [3], were estimated by correlating two
maps of ESRD incidence and the amount of expenses
prescribed on statins in Japan. Annually, the Japanese
Society for Dialysis Therapy reports the numbers of pa-
tients entering maintenance dialysis in each prefecture of
Japan [4]. We used the findings for 1996 to 2000 to corre-
late the regional ESRD distribution with regional differ-
ences in annual amounts paid for antihypertensive drugs
and statins during the same 5 years (Crecon Research
& Consulting, Inc., Tokyo, Japan) (Table 1). Multiple re-
gression analysis identified converting enzyme inhibitor
(F = 34.3) and statins (F = 7.1) as independently negative
factors arresting the progression of nephropathies, while
total antihypertensives as positive factors (F = 17.8). Re-
nal protective actions of statins, in addition to converting
enzyme inhibitors, those of which we already reported [2],
were revealed by analyzing ESRD map. Our epidemio-
logic approaches for Japan as a whole seemed useful to
estimate the renoprotective actions of certain agents that
have not been clarified by large-scale clinical trials.
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Table 1. Regional differences in annual incidence of ESRD and
usage of stain (1996 to 2000)
ESRD incidencea Usage of statina
Region million/year yen/person/year
1. Hokkaido 257 ± 5 2510 ± 120
2. Tohoku 222 ± 5 2090 ± 71
3. Kanto 230 ± 5 1760 ± 80
4. Koshinetsu 221 ± 10 1780 ± 90
5. Hokuriku 213 ± 7 2430 ± 90
6. Tokai 235 ± 6 1820 ± 80
7. Kinki 243 ± 7 2040 ± 70
8. Chyugoku 228 ± 7 2110 ± 100
9. Shikoku 267 ± 8 2090 ± 60
10. Kyushu 268 ± 5 1840 ± 70
11. Okinawa 284 ± 5 1090 ± 60
Regions are from north (1, Hokkaido) to south (11, Okinawa). Mean ± SEM.





To the Editor: A recent study by Ram et al [1] criticizes
earlier randomized, controlled trials on their statistical
validity, but itself exhibits major statistical flaws.
The authors in [1] criticize others [2] for having a
“surveillance group [that] had more prior interventions
than the control group.” Yet in their own study, it ap-
pears that the entry percutaneous transluminal angio-
plasty (PTA) rate in the control group was 2.5 times
higher than the flow group (Table 1, row 2).
The authors in [1] also criticize others [3] for having a
“group [that] had a high thrombosis rate because of mul-
tiple thromboses in a small number of grafts.” Yet the au-
thors admit to this very shortcoming for their flow group,
and explain that its high thrombosis rate “is misleading
in that it was caused by multiple thromboses in three
grafts.” The poor comparability between their groups is
even more pronounced when assessing entry graft age
(Ram et al [1], Table 2) where removing not three, but
one graft from the control group makes it 9.6 months
younger (P = 0.043) than the flow group! These dispari-
ties suggest a lack of uniformity among the three groups
on the very issues being studied: PTA rate, thrombotic
events (Table 1, Row 1), and graft survival (age).
The lack of group uniformity for these crucial param-
eters is a consequence of the small number of patients
inadequate for the high values of variation coefficient ra-
tio of standard deviation to mean value (S/M) (Table 1,
rows 3 and 4). To achieve credible data, Bland [4] suggests
that authors should choose the number of patients based
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Table 1. Comparison of graft characteristics derived from Table 2
and Figure 4 of Ram et al study [1]
Control Flow Stenosis
group group group
N = 34 N = 32 N = 35
1 No. of rethrombosis eventsa 2 14 1
2 Entry PTA rate/patient yearb 1.46 0.58 0.70
estimation from Table 2
3 Entry graft age days S/M 1.6 1.5 1.2
4 Entry no. of PTA S/M 1.6 1.4 1.5
S/M, ratio of standard deviation to mean value.
aNot included are rethrombosis events that occurred before Qa could be
measured.
bEntry thrombosis rates, rates of preemptive PTA (the crucial parameters of
this study), and methodology of calculations were not presented by authors in
Table 2 nor in Methods. The author (W.D.P.) declined to clarify. We estimated
PTA rate/patient by dividing entry PTA events by entry graft age days.
on the value of variation coefficient. This study would
need at least 140 patients in each group to credibly iden-
tify differences of 30% (95th percent CI) [4]. At 32 to 35
patients per group, observed variations between groups
must differ by a factor of more then 2.5 to have statistical
credibility.
The fact that data of just one to three grafts re-
verses major statistical outcomes of a 2.3-year study gives
evidence to inadequate group size in relation to the
study purpose. This compromises the authors’ clinical
conclusions.
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Reply from the Authors
Krivitski et al [1] represent Transonic Corporation, the
manufacturer of the ultrasound dilution device that is
widely used to measure access blood flow (Qa). We share
their disappointment that Qa surveillance did not prolong
graft life in our randomized controlled trial [2]. We have
the following response to their criticisms:
1. They have not accurately described the context of
our comments concerning previous studies. Our in-
tent was to show that the role of surveillance has
not yet been established.
2. They claim that our study had inadequate sample
size and that there was poor comparability between
groups.
A. The primary end point of our study was graft sur-
vival. Our 95% CI shows that if Qa surveillance
increased probability of graft survival, it was by
less than 0.25 at 2 years. This result shows that
if surveillance improves survival, it is modest
at best, and far less than in landmark, nonran-
domized studies (which have reported 4-fold im-
provements in survival). Krivitski et al are apply-
ing an unrealistic standard when they demand
adequate sample size for all possible compar-
isons, whether or not they are study end points.
B. Our study used the proportional hazards model
to test whether adjustment for the influence of
a number of variables (graft age, etc.) affected
study outcome. We reached the same conclusion:
there is no evidence that surveillance prolonged
graft life.
3. Their calculation of rethrombosis events is invalid
since they did not include all such events. Moreover,
note that the relatively high thrombosis rate in the
flow group was due to failures of flow surveillance.
4. Their comparison of prestudy PTA rates is invalid
since it did not take into account when PTAs oc-
curred (PTAs just before vs. remote from study en-
try do not have the same significance).
We appreciate the passionate commitment of mem-
bers of Transonic Corporation to their ultrasound dilu-
tion device. Nevertheless, we hope this commitment will
not keep them from applying a balanced view when eval-
uating surveillance studies. We believe they have much to
contribute to improving the management of hemodialysis
accesses.
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